Roche Announces FDA Approval Of Label Expansion For VENTANA PD-L1 Assay
6/3 07:11
(RTTNews) - Roche (RHHBY) announced the FDA has approved the VENTANA PD-L1 Assay as a companion diagnostic to identify non-small cell lung cancer patients eligible for treatment with Libtayo, a PD-1 inhibitor therapy developed by Regeneron. The company noted that the VENTANA PD-L...